Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 17;4(1):vdac057.
doi: 10.1093/noajnl/vdac057. eCollection 2022 Jan-Dec.

Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database

Panagiotis Kerezoudis  1 , Yagiz Ugur Yolcu  1 , Nadia N Laack  2 , Michael W Ruff  3 , Soumen Khatua  4 , David J Daniels  1 , Terry C Burns  1 , Sani H Kizilbash  5
Affiliations

Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database

Panagiotis Kerezoudis et al. Neurooncol Adv. .

Abstract

Background: The management of pineal parenchymal tumors remains controversial.

Methods: The 2004-2017 National Cancer Database was queried for cases (age >3 years) with histologically confirmed pineal parenchymal tumors of intermediate differentiation (PPTID, n = 90) or pineoblastoma (n = 106).

Results: Within the PPTID group, median age was 41 years; 49% were males. Five- and 10-year survival were 83% and 78%, respectively. Adjuvant radiation and chemotherapy were administered in 64% and 17% patients, respectively. The effect of radiation with or without chemotherapy (HR 1.15, P = .81, and HR 1.31, P = .72, respectively), and extent of resection (HR = 1.07, P = .93) was not significant. Within the pineoblastoma group, median age was 25 years; 51% were males. Five- and 10-year survival were 66% and 42%, respectively. Adjuvant radiation and chemotherapy were administered in 72% and 51%, respectively. In multivariable analysis, patients with pineoblastoma who received both radiation and chemotherapy (n = 39) had significantly lower hazard of death (HR 0.35, 95% CI 0.14-0.85, P = .02) compared to those who received radiation alone (n = 20) or no adjuvant treatment (n = 19). Finally, females in the pineoblastoma group were found to have a lower hazard of death compared to males (HR 0.24, 95% CI 0.10-0.58, P = .001); this comparison trended toward statistical significance in the PPTID subgroup (HR 0.40, 95% CI 0.14-1.08, P = .07).

Conclusions: Survival rates were higher in patients with PPTID vs patients with pineoblastoma. Adjuvant chemoradiation was associated with improved survival in pineoblastoma and females had lower hazards of death. Further research should identify specific patient profiles and molecular subgroups more likely to benefit from multimodality therapy.

Keywords: National Cancer Database; chemotherapy; pineal parenchymal tumor; radiation; survival.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves by treatment group within pineal parenchymal tumors of intermediate differentiation, for patients >3 years with available survival data (chemotherapy alone group excluded due to n = 1).
Figure 2.
Figure 2.
Kaplan-Meier survival curves by treatment group within pineoblastomas, for patients >3 years with available survival data (chemotherapy alone group excluded due to n = 3).
See this image and copyright information in PMC

References

    1. Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(Supplement_1):iv1–iv96. - PMC - PubMed
    1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. - PubMed
    1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
    1. Das P, Mckinstry S, Devadass A, Herron B, Conkey DS. Are we over treating pineal parenchymal tumour with intermediate differentiation? Assessing the role of localised radiation therapy and literature review. SpringerPlus. 2016;5:26. - PMC - PubMed
    1. Stoiber EM, Schaible B, Herfarth K, et al. Long term outcome of adolescent and adult patients with pineal parenchymal tumors treated with fractionated radiotherapy between 1982 and 2003—a single institution’s experience. Radiat Oncol. 2010;5(1):1–7. - PMC - PubMed

LinkOut - more resources